Compare Sincere Co., Ltd. (Japan) with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 45.32
2
Healthy long term growth as Operating profit has grown by an annual rate 29.93%
3
Negative results in Dec 25
4
With ROE of 13.85%, it has a very attractive valuation with a 1.62 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,424 Million (Micro Cap)
12.00
NA
0.00%
0.00
11.59%
1.23
Revenue and Profits:
Net Sales:
2,037 Million
(Quarterly Results - Dec 2025)
Net Profit:
17 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.73%
0%
-16.73%
6 Months
-22.49%
0%
-22.49%
1 Year
-7.25%
0%
-7.25%
2 Years
-10.76%
0%
-10.76%
3 Years
-19.71%
0%
-19.71%
4 Years
-8.94%
0%
-8.94%
5 Years
-49.21%
0%
-49.21%
Sincere Co., Ltd. (Japan) for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.03%
EBIT Growth (5y)
29.93%
EBIT to Interest (avg)
45.32
Debt to EBITDA (avg)
0.60
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
1.38
Tax Ratio
32.77%
Dividend Payout Ratio
40.22%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.92%
ROE (avg)
8.80%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.62
EV to EBIT
8.12
EV to EBITDA
6.96
EV to Capital Employed
1.53
EV to Sales
0.70
PEG Ratio
0.18
Dividend Yield
NA
ROCE (Latest)
18.86%
ROE (Latest)
13.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
2,036.80
1,867.80
9.05%
Operating Profit (PBDIT) excl Other Income
150.40
139.90
7.51%
Interest
5.70
5.70
Exceptional Items
-62.40
8.70
-817.24%
Consolidate Net Profit
17.20
77.30
-77.75%
Operating Profit Margin (Excl OI)
63.60%
63.70%
-0.01%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 9.05% vs -6.21% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -77.75% vs -5.04% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
7,456.10
6,539.40
14.02%
Operating Profit (PBDIT) excl Other Income
619.40
564.60
9.71%
Interest
22.90
16.90
35.50%
Exceptional Items
-66.50
2.80
-2,475.00%
Consolidate Net Profit
264.30
309.10
-14.49%
Operating Profit Margin (Excl OI)
70.30%
74.10%
-0.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.02% vs 9.69% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -14.49% vs 4.60% in Dec 2024
About Sincere Co., Ltd. (Japan) 
Sincere Co., Ltd. (Japan)
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






